Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial. - Bikdeli B; Hogan H; Morrison RB; Fanikos J; Campia U; Barns BM; Pfeferman MB; Snyder JE; Khairani CD; Goldhaber SZ; Piazza G (Thrombosis and haemostasis, 2022)